Notice2024-01364
Government-Owned Inventions; Availability for Licensing
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
January 24, 2024
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Abstract
The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.
Full Text
<html>
<head>
<title>Federal Register, Volume 89 Issue 16 (Wednesday, January 24, 2024)</title>
</head>
<body><pre>
[Federal Register Volume 89, Number 16 (Wednesday, January 24, 2024)]
[Notices]
[Page 4610]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2024-01364]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The invention listed below is owned by an agency of the U.S.
Government and is available for licensing to achieve expeditious
commercialization of results of federally-funded research and
development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing.
FOR FURTHER INFORMATION CONTACT: Ben Hurley at 240-669-5092, or
<a href="/cdn-cgi/l/email-protection#4a282f24202b27232464223f38262f330a242322642d253c"><span class="__cf_email__" data-cfemail="e78582898d868a8e89c98f92958b829ea7898e8fc9808891">[email protected]</span></a>. Licensing information may be obtained by
communicating with the Technology Transfer and Intellectual Property
Office, National Institute of Allergy and Infectious Diseases, 5601
Fishers Lane, Rockville, MD 20852: tel. 301-496-2644. A signed
Confidential Disclosure Agreement will be required to receive copies of
unpublished information related to the invention.
SUPPLEMENTARY INFORMATION:
Hybridoma Cell Lines 2A4 and 5B12 Against Puromycin Description of
Technology
Protein translation is a central cellular function attracting
increasing attention from cell biologists as they integrate gene
product specific information into a systems view of cellular function.
Scientists at NIAID developed the puromycin-specific antibodies that
allow for the specific detection of puromycin-containing nascent
polypeptides via standard immunofluorescence or flow cytometry. The
resulting ribopuromycylation method (RPM) localizes translation in
cells and can be applied to any PMY-sensitive eukaryotic or prokaryotic
cell to study the dynamics of protein synthesis at the cellular level
and investigate translational processes. It can also be used in vitro
or in vivo to measure the number of translating ribosomes using flow
cytometry.
This technology is available for licensing for commercial
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as
well as for further development and evaluation under a research
collaboration.
Potential Commercial Applications:
<bullet> Broad application for studying protein translation.
Competitive Advantages:
<bullet> This technology generates antibodies specific for puromycin
that can be used to localize translating ribosomes in all cell types.
Development Stage:
<bullet> Research Materials
Inventors: Jonathan Yewdell, MD, Ph.D., Alexandre David, Ph.D.,
both of NIAID.
Publications: David A. Dolan BP, Hickman HD, Knowlton JJ, Clavarino
G, Pierre P, Bennink JR, Yewdell JW. Nuclear translation visualized by
ribosome-bound nascent chain puromycylation. J Cell Biol. 2012 Apr
2;197(1):45-57. doi: 10.1083/jcb.201112145. PMID: 22472439; PMCID:
PMC3317795.
Also: PMID 29552591, 27385780, 25311127, 23229864.
Intellectual Property: HHS Reference No. E-003-2021.
Licensing Contact: To license this technology, please contact Ben
Hurley at 240-669-5092, or <a href="/cdn-cgi/l/email-protection#2143444f4b404c484f0f4954534d4458614f48490f464e57"><span class="__cf_email__" data-cfemail="1577707b7f74787c7b3b7d606779706c557b7c7d3b727a63">[email protected]</span></a>, and reference E-
003-2021.
Collaborative Research Opportunity: The National Institute of
Allergy and Infectious Diseases is seeking statements of capability or
interest from parties interested in collaborative research to further
develop, evaluate, or commercialize this technology. For collaboration
opportunities, please contact Ben Hurley at 240-669-5092, or
<a href="/cdn-cgi/l/email-protection#6f0d0a01050e02060141071a1d030a162f01060741080019"><span class="__cf_email__" data-cfemail="dcbeb9b2b6bdb1b5b2f2b4a9aeb0b9a59cb2b5b4f2bbb3aa">[email protected]</span></a>.
Dated: January 19, 2024.
Surekha Vathyam,
Deputy Director, Technology Transfer and Intellectual Property Office,
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2024-01364 Filed 1-23-24; 8:45 am]
BILLING CODE 4140-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on January 24, 2024.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.